anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an antioxidant which has a high antioxidant activity and is highly safe by incorporating conchiolin and kojic acid in combination. CONSTITUTION:The antioxidant contains conchiolin and kojic acid as active ingredients. Conchiolin is a scleroprotein contained in shells, pearls, etc., and is present in a relatively large amount in the shells of pearl oyster, hard-shelled mussel, fresh-water mussel, etc. The amounts (on a solid basis) of the conchiolin and the acid are desirably at least 0.007wt.% and at least 0.014wt.%, respectively. The generally preferred range of the amount of each ingredient is from 0.5wt.% to 3wt.%. A mixture of conchiolin or a hydrolyzate thereof and kojic acid or a fermentation extract containing the acid is applicable as an antioxidant to cosmetics such as a cream, a lotion, and a cleaning foam. Addition of this antioxidant to foods causes no problem because the main components thereof are amino acids, peptides, and kojic acid.
Armodafinil tablets are a wakefulness-promoting agent for oral administration. Armodafinil is the R-enantiomer of modafinil which is a 1:1 mixture of the R- and S-enantiomers. The chemical name for armodafinil is R-(-)-2-[(Diphenylmethyl)sulfinyl]acetamide. The molecular formula is C15H15NO2S and the molecular weight is 273.35.

The chemical structure is: 

Armodafinil is a white to off-white powder that is slightly soluble in water, sparingly soluble in acetone, and soluble in methanol.

Armodafinil tablets contain 50, 150, or 250 mg of armodafinil and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate and povidone.
Late onset dementia \>= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
Standard therapy offered until development of symptoms of heart failure decompensation occurs. Patients will be monitored until out of alert and at 30, 60, and 90 days.
Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Cognitive processing speed is defined as response accuracy at a given display duration, regardless of motor speed. Training involves detection, localization, and discrimination of briefly displayed stimuli (17-500 milliseconds) using tasks with varying demands on visual attention. Speed of processing is defined as response accuracy at a given display duration, regardless of motor speed. Training consists of 10 lab-based sessions over 5 weeks, followed by home-based practice on a tablet computer for 24 months with supportive home visits.
Pathogenic variants in CACNA1E are associated with early-onset epileptic and developmental encephalopathy (DEE). Severe to profound global developmental delay, early-onset refractory seizures, severe hypotonia, and macrocephaly are the main clinical features. Patients harboring the recurrent CACNA1E variant p.(Gly352Arg) typically present with the combination of early-onset DEE, dystonia/dyskinesia, and contractures. We describe a 2-year-and-11-month-old girl carrying the p.(Gly352Arg) CACNA1E variant. She has a severe DEE with very frequent drug-resistant seizures, profound hypotonia, and episodes of dystonia and dyskinesia. Long-term video-EEG-monitoring documented subsequent tonic asymmetric seizures during wakefulness and mild paroxysmal dyskinesias of the trunk out of sleep which were thought to be a movement disorder and instead turned out to be focal hyperkinetic seizures. This is the first documented description of the EEG findings in this disorder. Our report highlights a possible overlap between cortical and subcortical phenomena in CACNA1E-DEE. We also underline how a careful electro-clinical evaluation might be necessary for a correct discernment between the two disorders, playing a fundamental role in the clinical assessment and proper management of children with CACNA1E-DEE.
PURPOSE:The titled preparation useful as a sustained release preparation, raising drug releasability, containing a drug compound having percutaneous absorption, blended with a fatty acid ester, etc., as an active ingredient and a silicone elastomer as a maintaining carrier for the active ingredient. CONSTITUTION:A percutaneous absorption preparation containing a drug compound having percutaneous absorption so an active ingredient and a silicone elastomer as a maintaining carrier for the active ingredient. The drug compound is blended with a fatty acid ester or a sugaralcohol or both to raise drug releasability. Penicillin, aspirin, diazepam, vitamin, etc., maybe cited as the drug compound. Propylene glycol caprate, etc., may be used as the fatty acid ester. Since the preparation has high drug releasability and a necessary and sufficient amount of the drug is absorbed through the skin, application is easy and side effects can be suppressed.
Provided is a  Lactobacillus salivarius  belonging to  Lactobacillus salivarius  subsp. Salivarius, and deposited in China General Microbiological Culture Collection Center with an accession number CGMCC NO: 3606. Further provided is a method for preparing a metabolite of the  Lactobacillus salivarius , wherein the  Lactobacillus salivarius  is as described above. Further provided is a composition, comprising viable strains of the  Lactobacillus salivarius  and/or the metabolite of the  Lactobacillus salivarius  prepared as described above. Further provided is a use of the composition in preparation of drugs for prevention and/or treatment of cancers and a method for treating and/or preventing cancers. The viable strains of  Lactobacillus salivarius  and the metabolite of  Lactobacillus salivarius  provided in the present invention can both remove the genotoxicity of 4-NQO in vivo, thus exerting an effect of effectively preventing and/or treating cancers.
The invention relates to a cosmetic sunscreen preparation, which is provided in the form of a foaming oil-in-water emulsion inside a foam dispenser, whereby the oil-in-water emulsion, with regard to the total composition, comprises 2-50 wt. % of an oil phase and 50-98 wt. % of a water phase that contains a surfactant. In addition, the oil phase and/or the water phase of the emulsion contain(s), with regard to the total composition, UV-A and/or UV-B absorbers in a quantity of 1-40 wt. % of which the oil phase contains 1-30 wt. % and the aqueous phase contains 0-10 wt. % of the UV absorbers. The oil-in-water emulsion also optionally contains a designated quantity of cosmetic auxiliary agents, especially preservatives and/or perfumes and/or agents used for increasing the resistance to water.
Objectives : The main objective of this study was to investigate the relation between ceramic brackets and the development of WSL compared to that associated with conventional metal brackets.

Study design: Randomized 2-parallel arm clinical trial. Materials and methods: Quantitative light induced fluorescence (QLF) images were taken for the two randomly allocated groups (Ceramic group, n=26; Metal group, n=25) of patients at T0: before the start of treatment; T1: after 2 months and T2: at 4 months after treatment). The QLF images were analyzed; Primary outcome measures: The lesion area (Pixels) and Mean amount of fluorescence loss (∆F)% and the number of newly developed lesions. Secondary outcome: Maximum fluorescence loss (∆F-Max)% and plaque surface area (∆R 30)%. Means and standard deviations for all the measured parameters at T0, T1 and T2 were calculated. Split plot analysis of variance (SPANOVA) test was used to determine the changes within each group at the different time intervals, and between the two groups. Chi square was used to compare between the two groups regarding the number of new lesions during the treatment. P value was set at 0.05 level.
The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as found in glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with another therapeutic agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure. The present invention also provides a novel composition comprising a nucleoside 5′-pyrophosphate pyranoside or analogues.
Specialized nutraceutical formulated in softgel. Participants are instructed to take 2 softgels orally with some water, one before breakfast and one before diner.
The invention relates to a pantoprazole sodium enteric coatel tablet composition and a preparation method thereof. The composition is characterized by consisting of a proton pump inhibitor pantoprazole sodium and a gastrointestinal excitomotor itopride hydrochloride. The composition is used for treating gastric ulcer, gastroesophageal reflux diseases and functional dyspepsia. In the combined preparation, the weight ratio of pantoprazole sodium and itopride hydrochloride is (2:5)(-2:10). Compared with a single component preparation, the cure rate is relatively increased remarkably, the occurrence rate of untoward effect is greatly reduced, and the symptom recurrence rate is remarkably reduced. The composition has important effect of treating gastric ulcer, gastroesophageal reflux diseases and functional dyspepsia, and is simple and convenient in preparation method, low in cost, suitable for oral administration of patients and good in compliance.
GCA and TAK both cause inflammation in the lining of the arteries, which can interfere with the body's ability to carry oxygen to areas that need it. Symptoms of GCA include headaches, jaw pain, and blurred or double vision. Serious symptoms that occur less commonly are blindness and stroke. TAK symptoms include fever, fatigue, weight loss, arthritis, and non-specific aches and pains. There may also be tenderness near affected arteries. Researchers believe that GCA and TAK are diseases that are controlled by the body's immune system. Activated T-cells, specifically, are critical to the origin and development of these diseases. Abatacept is a medication that modulates the signal required for T-cell activation. This study will evaluate the safety and effectiveness of abatacept in treating GCA and TAK and preventing disease relapse.

Participation in this study may last up to 4 years. Participants will receive abatacept intravenously on specified days during Months 1, 2, and 3. They will also receive daily prednisone, which will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to either continue abatacept or be switched to placebo infusions. Both treatments will be given once a month at study visits. Blood samples will also be collected at the monthly study visits to conduct laboratory-based studies. Participants who remain in remission will continue to receive abatacept or placebo monthly until the common closing date, defined as 12 months after enrollment of the 33rd participant for each disease.
The parcicipants were randomly assingned to epidural infusion group and femoral sciatic block. In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation. In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr. The incidence of side effects is measured.
OBJECTIVE: This current study represents a novel endeavor to scrutinize the correlation between the temporal alteration in serum total bilirubin (TBIL) concentrations and the rate of estimated glomerular filtration rate (eGFR). Additionally, this study aims to probe the plausible molecular mechanism underpinning the renoprotective effects of bilirubin concerning its hormonal characteristics.
MATERIALS AND METHODS: In this study, a cohort of 103 patients diagnosed with DKD and receiving medical care at Dongzhimen Hospital were recruited and monitored over a period of 2-7 years. The progression of DKD was ascertained using a threshold of eGFR decline > -5.48%/year. To assess the relationship between the annual change in serum TBIL levels (%/year) and the slope of eGFR, multivariate binary logistic regression analysis was employed. Furthermore, the ROC curve analysis was employed to determine the cut-off value for TBIL levels (%/year).
RESULTS: The use of multivariate binary logistic regression models revealed that serum TBIL levels (%/year) exhibited a significant correlation with the slope of eGFR. Moreover, the ROC curve analysis indicated a cut-off value of -6.729%/year for TBIL levels (%/year) with a sensitivity of 0.75 and specificity of 0.603, in diagnosing eGFR decline >-5.48%/year.
CONCLUSIONS: The findings of this study suggest that the sustained elevation of serum bilirubin concentration within the physiological range can effectively retard the progression of Diabetic Kidney Disease (DKD). Furthermore, the hormonal attributes of bilirubin may underlie its renoprotective effects.
Participants receive docetaxel at 75 mg/m\^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
Ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) is a common clinical syndrome with high morbidity and mortality. Ferroptosis, a newly discovered form of oxidative cell death, is involved in the pathogenesis of renal I/R injury; however, the underlying mechanism remains to be explored. Here, we reported that site 1 protease (S1P) promotes ischemic kidney injury by regulating ferroptotic cell death of tubular epithelial cells. S1P abundance was measured in hypoxia/reoxygenation (H/R)-treated Boston University mouse proximal tubular (BUMPT) cells and I/R-induced murine kidney tissue. S1P expression in BUMPT cells and kidneys was initially activated by hypoxic stimulation, accompanied by the ferroptotic response. Blocking S1P blunted H/R-induced ferroptotic cell death, which also restored sirtuin 3 (SIRT3) expression and superoxide dismutase 2 (SOD2) activity in BUMPT cells. Next, inhibition of S1P expression restored I/R-suppressed SIRT3 abundance, SOD2 activity and reduced the elevated level of mitochondria reactive oxygen species (mtROS), which attenuated tubular cell ferroptosis and renal I/R injury. In conclusion, S1P promoted renal tubular epithelial cell ferroptosis under I/R status by activating SIRT3-SOD2-mtROS signaling, thereby accelerating kidney injury. Thus, targeting S1P signaling may serve as a promising strategy for I/R kidney injury.
PURPOSE: An antioxidant cosmetic containing an Albizzia julibrissin Duraz. extract as a main component is provided. Because the extract is low in skin irritation and stability during mixing and shows an excellent free radical scavenging effect, it can provide an antioxidant cosmetic having an excellent prevention effect on wrinkles and skin aging. CONSTITUTION: The extract is prepared by extracting Albizzia julibrissin Duraz. in C1-3 anhydrous or hydrous alcohol, or ethyl acetate at 4 to 30deg.C for 3 to 20 days and then concentrating, wherein before or after execution of the extraction process, a diethylether soluble component is removed from the extract. The antioxidant cosmetic contains 0.0001 to 5% by weight of an Albizzia julibrissin Duraz. extract, based on the total dried weight of the antioxidant cosmetic.
Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
A method for extracting hypoglycemic peptide from tea seed meal comprises the following steps: (1) pulverizing tea seed cake. (2) Tea seed meal is degreased. (3) And (3) extracting tea seed meal protein. (4) Preparing tea seed meal crude peptide. (5) Separating and screening the alpha-glucosidase inhibitory peptides. (6) And (3) structural identification of the alpha-glucosidase inhibitory peptide. Through the steps, the invention prepares three alpha-glucosidase inhibitory peptides, the amino acid sequences of which are a (GHSLESIK), b (GLTSLDRYK) and c (SPGYYDGR) in sequence, has very high inhibitory activity to alpha-glucosidase, and has very wide application prospect in the development of blood sugar reducing products. The raw materials related by the invention are cheap and have wide sources, and the prepared alpha-glucosidase inhibitory peptide has high activity and wide application prospect.
The invention relates to traditional Chinese medicine cinnabar-saltpeter powder for treating pediatric epilepsy. The traditional Chinese medicine cinnabar-saltpeter powder is mainly used for solving the problem that the current drugs for treating pediatric epilepsy are poor in treatment effect and have side effects. The traditional Chinese medicine cinnabar-saltpeter powder is prepared through the steps of weighing 15-18 parts of raw white alum, 15-18 parts of cinnabar, 15-18 parts of red halloysite and 15-18 parts of saltpeter, baking, co-grinding into fine powder, and grinding garlic paste, so as to pill in the size of mung beans. The pill is orally taken by 2g once every day for the adult, and the dosage for children is halved; the pill can be orally taken continuously. The traditional Chinese medicine cinnabar-saltpeter powder has the aims and advantages that the total effective rate for pediatric epilepsy treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine cinnabar-saltpeter powder is free from toxic and side effects.
Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
OBJECTIVES: Hip and groin pain is common in Gaelic games players, but data are limited to elite males with poor representation of females. The aim of this study was to examine the prevalence, severity and factors associated with hip and groin pain and Femoroacetabular Impingement Syndrome (FAIS) in male and female Gaelic games players.
METHODS: A representative national sample of Gaelic games players completed a survey providing demographic information and details related to self-reported episodes of hip and groin pain and FAIS diagnosis within the last year. Players from multiple age grades, codes (Football/Hurling/Camogie) and levels of Gaelic games were included.
RESULTS: A total of 775 players responded to the survey. The annual prevalence of hip and groin pain was 54.8%. Almost half of players (48.8%) continued to participate in sport, while 18.7% ceased participation and 32.5% reported reduced participation. Although 40% of episodes lasted no longer than 3 weeks, there was a high recurrence rate (33.5%). FAIS was reported by eight players, representing 1.9% of hip and groin complaints. Logistic regression models indicate male sex, playing both codes of Gaelic games and participating in additional sport were significant factors in predicting hip and groin pain.
CONCLUSION: Hip and groin pain is prevalent in Gaelic Games with FAIS accounting for a small proportion of cases. However, consideration of indicators of severity (participation impact/symptom duration/medical attention) is essential in understanding the context and magnitude of these hip and groin issues. Male players and players engaging in multiple sports are more likely to experience hip and groin pain.
An abrasive base which is inhibited from reacting with NaF; and a process for producing the abrasive base. The process for abrasive base production comprises heating anhydrous calcium secondary phosphate in the presence of a magnesium compound and a polyphosphate. The amount of the magnesium compound to be present in terms of magnesium amount is in the range of 1,500-5,000 ppm of the anhydrous calcium secondary phosphate. The amount of the polyphosphate to be present is such that the molar ratio of the cation ingredient as a component of the polyphosphate to the magnesium in the magnesium compound is from 0.4/n to 12/n (wherein n is the valence of the cation ingredient). The heating is conducted at a temperature in the range of 100-300°C. The abrasive base contains magnesium and a polyphosphate and comprises, as the main component, anhydrous calcium secondary phosphate inhibited from reacting with a fluorine compound. The magnesium content is 1,500-5,000 ppm and the molar ratio of the cation ingredient contained as a component of the polyphosphate to the magnesium contained is from 0.4/n to 12/n.
PURPOSE:To obtain dental cement having improved handleability, and shelf stability, by blending a cement powder component with part of a polymer in a powder state, keeping the blend, processing the residue of the polymer into an aqueous solution, leaving it, kneading both the components and setting them when they are set. CONSTITUTION:Dental cement obtained by blending a cement powder component (e.g., zinc oxide, magnesium oxide, etc.) with part of a polymer, preferably 1- 10wt% polymer in a powder state, keeping the blend, leaving the residue of the polymer as an aqueous solution, kneading and setting both the components when they are set. A polymer, copolymer, etc. of acrylic acid, methacrylic acid, vinylsulfonic acid, etc. may be cited as the example of the polymer. Demerit of existing polycarboxylate cement can be solved by simple operation in which a small amount of the polymer component in a powder state is added to the cement powder component.
The objective of the study is to determine the effects of progressive eccentric exercises verses Bodyweight exercises on agility, power and functional performance in athletes with hamstring strain. The study is randomized and single blinded. Ethical approval is taken from ethical committee of Riphah international university Lahore. Participants who meet the inclusion criteria will be enrolled and allocated in group A and group B through sealed envelope method by non probability convenient random sampling technique. Subjects in group A will receive Progressive eccentric exercises. Group B will receive Bodyweight exercises. The outcome measures will be assessed by T test, Vertical jump, Standing Long jump and squat test. The data will be analyzed by SPSS, Version 25. Statistical significance is P=0.05.